Summit Corporation Aktie
WKN DE: A115K3 / ISIN: GB00BN40HZ01
|
09.09.2025 11:51:00
|
Is Summit Therapeutics a Buy, Sell, or Hold Now?
A rocky road for Summit Therapeutics got a lot rougher over the weekend. The company presented somewhat disappointing data for the experimental cancer drug it's developing.When the market opened on Monday, Sep. 8, shares of the pre-commercial biotech stock had fallen 17% from the previous session's closing price. While ivonescimab's path forward isn't as clear as investors had hoped it would be, it's still a long way from hopeless.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!